Watch out, Novo Nordisk. Lilly's new dual action diabetes med could pressure Ozempic: analyst

Novo Nordisk’s Ozempic is already ducking it out with Eli Lilly’s Trulicity in the once-weekly diabetes treatment field. But looming competition from the Indianapolis pharma could pose a serious threat, especially at its lowest tested dose, one analyst said.